BiotechTube

Certican® + Neoral + Myfortic + Simulect® + Corticosteroids

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Renal Interstitial Fibrosis

Conditions

Renal Interstitial Fibrosis

Trial Timeline

Sep 1, 2009 → Jun 1, 2012

NCT ID
NCT01079143

About Certican® + Neoral + Myfortic + Simulect® + Corticosteroids

Certican® + Neoral + Myfortic + Simulect® + Corticosteroids is a phase 3 stage product being developed by Novartis for Renal Interstitial Fibrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01079143. Target conditions include Renal Interstitial Fibrosis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01079143Phase 3Completed

Competing Products

20 competing products in Renal Interstitial Fibrosis

See all competitors
ProductCompanyStageHype Score
MBX 2109 + MBX 2109 + MBX 2109 + MBX 2109MBX BiosciencesPhase 1
28
LY3473329Eli LillyPhase 1
33
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
44
SPR001Spruce BiosciencesPhase 2
44
SPR001Spruce BiosciencesPhase 2
44
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
44
TildacerfontSpruce BiosciencesPhase 2
44
Drotrecogin alfa activated (Xigris)Eli LillyPhase 2
52
LY3819469Eli LillyPhase 1
33
Atezolizumab + CabozantinibChugai PharmaceuticalPhase 3
77
DS-6000a + DS-6000aDaiichi SankyoPhase 1
33
DS-1093aDaiichi SankyoPhase 1
33
CS-3150Daiichi SankyoPhase 3
77
AGS-16C3FAstellas PharmaPhase 1
33
AGS-16M8FAstellas PharmaPhase 1
33
CP-461Astellas PharmaPhase 2
52
roxadustatAstellas PharmaPhase 3
77
YM178Astellas PharmaPhase 1
33
intravenous immunoglobulins (IVIG)Astellas PharmaPhase 1
33
bixalomerAstellas PharmaPre-clinical
23

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85